Also known as: Reditux, Truxima
Rituximab is a CD20-directed cytolytic monoclonal antibody used in hematologic malignancies and selected autoimmune diseases. U.S. labeling (RITUXAN) lists indications including non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis (with methotrexate), and granulomatosis with polyangiitis/microscopic polyangiitis. Initial U.S. approval was in 1997.
Two new studies clarify how Epstein-Barr virus may trigger multiple sclerosis: one shows a doubled CD4+ T cell response in untreated patients, while another reveals EBV-activated B cells cause brain inflammation in mice. Insights point to potential therapies targeting EBV-specific immune activity.
ASCO 2026 data show CBM588 boosts immunotherapy in kidney cancer and a bispecific combo improves lymphoma. Early-day ICI infusion, mezigdomide T cell reinvigoration, and dostarlimab maintenance also advance cancer immunotherapy.
China's 12th national Volume-Based Procurement round places RMB 60 billion across 65 drug varieties, accelerating generics and biosimilars substitution. Separately, Genialis launched BioBridge to help translate Chinese oncology trial results into Western development programs, as Chinese out-licensing hit $137.7 billion in 2025.
Epcoritamab plus lenalidomide cut progression risk by 60% in R/R DLBCL in a phase 3 trial. Five-year AUGMENT follow-up supports R2 in indolent NHL; a phase 2 penpulimab-lenalidomide-R-GemOx trial showed activity in DLBCL.
CO-005, a humanized anti-CD47 fusion protein from Caedo Oncology, showed potent antitumor activity in preclinical models of B-cell lymphoma, including rituximab-resistant tumors. The therapy induces programmed cancer cell death while disrupting immune checkpoints, offering a potential solution to CD20 resistance.
Long-term results from the phase III TRIANGLE trial show ibrutinib-based regimens improve survival in younger mantle cell lymphoma patients, while the ECHO trial establishes a new standard for older patients. Advances in CAR T-cell and bispecific antibody therapies are reshaping treatment for this rare blood cancer. The findings were presented at the annual MCL Consortium meeting.
At ASCO 2026, Rutgers and Ohio State researchers present new breast cancer combination data, lymphoma survival analyses, and a drug donation program that cut medication wait times to about six days.
US FDA approved Calquence (acalabrutinib) plus venetoclax as the first all-oral, fixed-duration regimen for adults with chronic lymphocytic leukaemia and small lymphocytic lymphoma. Approval based on AMPLIFY phase III trial showing 77% progression-free at three years vs 67% with chemoimmunotherapy. Regimen already cleared in EU, UK, and Canada.
Cellectar reported 12-month follow-up from the Phase 2b CLOVER WaM trial of iopofosine I 131 in relapsed or refractory Waldenström macroglobulinemia. In 55 patients, ORR was 83.6%, MRR was 61.8% and median duration of response was 17.8 months.
Three FcRn inhibitors are approved for generalized myasthenia gravis, with a head-to-head trial of efgartigimod and nipocalimab underway. Emerging therapies including telitacicept, gefurulimab, and CAR-T cell therapy (KYV-101) show promise, while Immunovant's batoclimab failed TED trials.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07764601 |
R-MA-PD-1 Versus R-MA in Treatment-naive Primary CNS Lymphoma |
NOT_YET_RECRUITING | NA |
| NCT07760610 |
Pomalidomide Plus Rituximab Maintenance in Young High-Risk Newly Diagnosed DLBCL After First-Line Response |
NOT_YET_RECRUITING | PHASE4 |
| NCT07731789 |
Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma |
NOT_YET_RECRUITING | PHASE2 |
| NCT07724457 |
Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma |
NOT_YET_RECRUITING | PHASE2/PHASE3 |
| NCT07714421 |
Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients |
NOT_YET_RECRUITING | PHASE1 |
| NCT07712588 |
Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19) |
NOT_YET_RECRUITING | PHASE2/PHASE3 |
| NCT07691606 |
A Study of ARC-02 in B-cell NHL |
RECRUITING | PHASE1 |
| NCT07675291 |
Rituximab Combining With Low-Dose Mycophenolate Mofetil on Proliferative Lupus Nephritis in Children |
NOT_YET_RECRUITING | NA |
| NCT07674745 |
Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary Fibrosis |
NOT_YET_RECRUITING | PHASE2 |
| NCT07662928 |
Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK Study |
NOT_YET_RECRUITING | PHASE2 |
